GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

Spread the love

GNS Healthcare

GNS Healthcare, the leader in the use of “Virtual Patients”, Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc.  a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases.

Recommended News:

GNS Healthcare Archives - CXOTV Health

Every year more than six million patients in the United States alone are diagnosed with Alzheimer’s, Parkinson’s, and Huntington’s diseases. These diseases are chronic, debilitating and there is substantial heterogeneity in the presentation of the symptoms and the rates of their progression among patients. The GNS Gemini Virtual Patient models help discover and unravel the complex biological circuitry of the diseases and predict patient response, which can help biopharmaceutical companies accelerate the discovery and development of new therapeutic options for patients

Under the terms of the agreement, Arvinas will leverage GNS’ Gemini Virtual Patient models to better understand the biology of the underlying disease, how it progresses, and how potential drugs might perform at the individual patient level. This will help Arvinas researchers discover and prioritize novel drug targets and drug candidates, simulate clinical trials to better understand drivers of diseases for various clinical outcomes, better select patients for clinical trials, and help determine which treatments are most effective for given patient types.

Angela Cacace, Ph.D., Senior Vice President of Neuroscience & Platform Biology at Arvinas, commented, “We believe this collaboration will provide novel insights and will help us understand the underlying mechanisms of complex neurodegenerative diseases to inform our discovery and development efforts with the aim of improving patient outcomes.”

Recommended News:

“We are committed to supporting the critical work Arvinas is doing to discover and develop breakthrough therapies that help patients who suffer from these conditions,” said Joseph F. Donahue, Chief Business Officer at GNS Healthcare. “These diseases impact so many families and we are proud to be able to help contribute to potential treatments that lead to better outcomes for them.”

Spread the love

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button